Drugs / UniFluVec
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04650971 | Aug 2019 → Mar 2020 | influenza | Pharmenterprises Biotech LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UniFluVec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04650971 ↗ |
| Modality | Vaccine | “universal influenza vector vaccine” NCT04650971 ↗ |
| Route | Intranasal | “Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks” NCT04650971 ↗ |